$1.47
+0.01 (+0.68%)
Open$1.48
Previous Close$1.46
Day High$1.49
Day Low$1.41
52W High$4.07
52W Low$0.81
Volume—
Avg Volume55.1K
Market Cap22.01M
P/E Ratio—
EPS$-0.90
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,006.8% upside
Current
$1.47
$1.47
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.88M | 5.29M | 3.86M |
| Net Income | -13,297,166 | -16,328,898 | -155,305 |
| Profit Margin | -343.0% | -325.8% | -4.0% |
| EBITDA | -14,090,477 | -18,264,365 | -205,551 |
| Free Cash Flow | — | — | -168,121 |
| Rev Growth | -26.7% | -26.7% | +19.6% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |